A new urine-based test, MyProstateScore 2.0 (MPS2), has demonstrated high sensitivity and accuracy in detecting grade group 2 or higher prostate cancer, according to a recent study published in the Journal of Urology.
Developed by Ganesh S. Palapattu, MD, FACS, and his team at the University of Michigan, the MPS2 test builds on the original MyProstateScore test, which includes PSA, gene fusion TMPRSS2::ERG, and PCA3 markers. The new test was validated using first-catch urine samples obtained prior to biopsy and showed excellent performance in detecting high-grade prostate cancer.
The study included 266 men with a median PSA level of 6.6 ng/mL, and found that the MPS2 test detected 94% of grade group 2 or higher cancers. This is significantly higher than other risk assessments such as prostate-specific antigen (PSA) and the Prostate Cancer Prevention Trial risk calculator.
In fact, the study found that the MPS2 test would have avoided 36% to 42% of unnecessary biopsies compared to other tests, which could lead to overdiagnosis and overtreatment. The test also showed high accuracy in detecting repeat biopsies, with a 46% to 51% reduction in unnecessary procedures.
The researchers believe that the MPS2 test has the potential to improve patient outcomes by allowing clinicians to focus on those who are most likely to have aggressive cancers. Palapattu stated that “MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers.”
Further studies are planned to validate the MPS2 test in a larger, more diverse population of patients.
Source: https://www.urologytimes.com/view/mps2-test-validated-for-detection-of-high-grade-prostate-cancer-in-non-dre-urine